Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COM 701 (Primary) ; COM 902 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Rectal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Compugen

    • Most Recent Events

    • 12 Nov 2024 According to a Compugen media release, company plan an adaptive platform trial starting with sub-study 1, randomizing patients with relapsed platinum sensitive ovarian cancer ineligible for PARPi or bevacizumab to single agent COM701 maintenance treatment or placebo.data from projected COM701 interim analysis from sub-study 1 expected H2 2026.
    • 07 Nov 2024 According to Florida Cancer Specialists & Research Institute media release, results from this study being presented this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston.
    • 05 Nov 2024 According to a Compugen media release, the data from this study presented at the Society for Immunotherapy of Cancer (SITC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top